BackDICE Therapeutics Overview

DICE Therapeutics Total Current Liabilities

Latest total current liabilities for DICE: $21M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$20.57M
70.49% YoYΔ $8.51M vs prior year quarter

Peer trimmed avg / median

Loading

DICE Therapeutics Total Current Liabilities History

Loading

DICE Therapeutics vs. peers: Total Current Liabilities Comparison

Loading

DICE Therapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

DICE Therapeutics (DICE) FAQ

DICE Therapeutics (DICE) currently reports a total current liabilities of $21M as of June 2023. That compares with $12M in the prior-year period — up 70.5% year over year. Use the charts on this page to explore DICE Therapeutics's total current liabilities history and peer comparisons.

DICE Therapeutics's total current liabilities increased from $12M to $21M — a 70.5% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

DICE Therapeutics reported $21M in total current liabilities as of June 2023. That compares with $12M in the prior-year period — up 70.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $21M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for DICE Therapeutics, and consider following DICE for alerts when major investors trade the stock.

DICE Therapeutics is classified in the Healthcare sector. On total current liabilities, it currently shows $21M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DICE with unrelated industries.